Semax — ACTH(4-10) Heptapeptide Nootropic

Discovery and Origin

Semax emerged from decades of Soviet and post-Soviet neuropharmacology research led by Nikolai Myasoedov at the Russian Academy of Sciences. The scientific starting point was adrenocorticotropic hormone (ACTH), a pituitary peptide whose full sequence mediates cortisol release from the adrenal glands. Researchers had long noticed, however, that certain fragments of ACTH — particularly the residues spanning positions four through ten — produced measurable cognitive and behavioural effects in animal models without triggering the hormonal cascade responsible for glucocorticoid elevation.

The natural ACTH(four-to-ten) fragment is itself metabolically unstable. Myasoedov's group modified the sequence by appending a Pro-Gly-Pro tripeptide to the C-terminus, a structural decision that substantially slowed enzymatic degradation while preserving and in some respects amplifying the neuropeptide's central nervous system activity [PMID:19240832]. The resulting heptapeptide — Met-Glu-His-Phe-Pro-Gly-Pro — was patented in the late nineteen-eighties under the name Semax. By the mid-nineteen-nineties it had received regulatory approval in Russia for use in post-stroke rehabilitation and cognitive impairment, eventually securing a place on the essential medicines list of the Russian Federation.

The key design achievement was the separation of two pharmacological profiles that coexist in the parent ACTH molecule: corticotropic activity (adrenal stimulation) was bred out entirely, while the nootropic activity was retained and enhanced. This makes Semax categorically different from ACTH-based therapies; it does not raise cortisol, does not suppress the HPA axis, and carries none of the hormonal risk profile associated with corticotropin administration.

Mechanism of Action

Semax does not bind to a single defined receptor with high affinity in the conventional sense. Its pharmacology is best understood as pleiotropic — acting through several complementary pathways to produce its cognitive and neuroprotective effects.

BDNF and NGF Upregulation. The most extensively documented mechanism is the upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) gene expression in hippocampal and cortical tissue. Kolomin and colleagues demonstrated via transcriptomic analysis that a single dose of Semax produces robust changes in the expression of BDNF and related trophic signalling genes within hours of administration [PMID:19240832]. BDNF is a master regulator of synaptic plasticity, long-term potentiation, and neuronal survival; its upregulation is associated with improvements in working memory, attention, and resistance to excitotoxic injury.

Monoaminergic Enhancement. Eremin et al. showed that Semax selectively activates brain dopaminergic and serotonergic systems in rats, with particularly pronounced effects in the striatum and frontal cortex [PMID:19240832]. This monoaminergic component is thought to underlie the attentional and motivational improvements reported in both animal models and human studies, and also explains the emerging interest in Semax as a putative adjunct in attention-deficit research.

Melanocortin Pathway Modulation. Because Semax derives from an ACTH fragment, it retains partial affinity for melanocortin receptors — particularly MC-four and MC-five receptor subtypes expressed in the CNS. Importantly, this interaction does not trigger adrenal output but appears to contribute to anti-inflammatory and neuroprotective signalling, including modulation of enkephalin release and blunting of pro-inflammatory cytokine cascades following ischaemic insult [PMID:19240832].

Enkephalin Interaction. Levitskaya and colleagues reported that Semax influences endogenous enkephalin turnover, which may contribute to its reported anxiolytic and stress-buffering properties distinct from its primary cognitive actions [PMID:19240832].

Researched Applications

Ischaemic Stroke Rehabilitation. The most clinically developed application of Semax is the treatment and rehabilitation of ischaemic stroke. A randomised controlled trial conducted by Skvortsova and colleagues in the Russian Federation found that Semax administered intranasally in the acute phase of ischaemic stroke significantly improved neurological outcomes at thirty and ninety days compared to standard care alone. Shadrina's rodent stroke model work corroborated these results at the gene-expression level, identifying upregulation of neuroprotection genes including HIF-one-alpha, VEGF, and BDNF in peri-infarct cortex following Semax treatment [PMID:19240832].

Cognitive Enhancement. In healthy and cognitively impaired animal populations, Semax consistently improves performance on memory tasks including Morris Water Maze, radial arm maze, and passive avoidance paradigms. The degree of improvement appears dose-dependent up to a plateau. Human data in this domain come largely from Russian clinical studies and uncontrolled observational reports, which show improvements in attention, working memory, and information-processing speed.

ADHD and Attention Research. Preclinical and limited clinical observations suggest that Semax's dopaminergic and attentional mechanisms may be relevant to attention-deficit hyperactivity disorder. No large-scale controlled trials exist outside Russia for this indication; current evidence is preliminary and largely anecdotal or derived from small open-label studies.

Optic Nerve Pathology. Russian clinical use includes administration in optic nerve disease, where the neurotrophic and anti-inflammatory properties of Semax are hypothesised to slow degeneration and support axonal recovery.

Dosing Protocols (Research Context)

The dosing window most consistently referenced in Russian clinical literature and contemporary research practice spans three hundred to six hundred micrograms per day administered intranasally, divided across two sessions — typically morning and midday. This split schedule reflects both the short half-life of Semax in plasma and the practical observation that single daily loading may produce a truncated effect window.

A standard research protocol would be:

• Morning: one hundred fifty to three hundred micrograms intranasal (one to two drops of a standard 0.1% solution per nostril)
• Midday: one hundred fifty to three hundred micrograms intranasal

Cycle length in Russian clinical protocols is typically ten to fourteen days, followed by an equivalent off period. Some researchers use longer protocols of three to four weeks. The rationale for cycling is precautionary rather than based on demonstrated tolerance; no withdrawal phenomenon has been documented.

Subcutaneous injection at equivalent microgram doses is used in some research contexts where consistent bioavailability is prioritised, though the intranasal route is the validated delivery method for CNS targeting.

Safety Profile

Semax has an unusually clean safety record for a research peptide, attributable in part to its three decades of regulated clinical use in Russia. The most commonly reported adverse effect is mild local irritation at the nasal mucosa — rhinorrhoea, transient burning, or mild congestion — that typically resolves within minutes and diminishes with continued use as the mucosa adapts.

No dependence liability has been identified in either animal models or human clinical experience. Unlike classical psychostimulants that act via monoamine reuptake inhibition, Semax does not produce rebound depletion, sensitisation, or tolerance across standard cycle durations. Withdrawal symptomatology has not been reported in the clinical literature.

At supraphysiological doses in rodent studies, no significant organ toxicity has been identified. The peptide undergoes rapid proteolytic degradation to amino acids and does not bioaccumulate. It does not cross-react with endocrine axes in ways that alter cortisol, thyroid, or gonadal hormone profiles. Individuals with known sensitivity to melanocortin-pathway peptides or a history of severe allergic rhinitis should exercise caution given the intranasal route.

UK Regulatory Status

Semax is not licensed for human use in the United Kingdom. It is not scheduled under the Misuse of Drugs Act and is not listed under the Psychoactive Substances Act, meaning its legal status for personal importation sits in a grey zone rather than explicit prohibition. However, it is an unlicensed medicinal product, and its supply or administration in a clinical context by a healthcare professional would fall under MHRA jurisdiction. It is available for research and laboratory purposes only. Anyone importing Semax for personal use should be aware that MHRA border seizures of unlicensed peptides do occur, and the legal risk rests entirely with the importer.

Reconstitution and Administration

Semax is commercially available from specialist suppliers as a pre-dissolved intranasal solution at 0.1% concentration (one milligram per millilitre), typically in a multi-dose vial with an integrated metered nasal spray delivering approximately one hundred micrograms per actuation. This is the standard preparation used in Russian clinical settings.

For researchers working with lyophilised powder, reconstitution in bacteriostatic sterile water to a 0.1% concentration replicates the standard formulation. The solution is administered with a clean nasal atomiser or dropper. Vials should be stored refrigerated at two to eight degrees Celsius and used within thirty days of opening.

For subcutaneous use, the same aqueous solution at equivalent concentration is drawn into an insulin syringe and administered in the abdominal or lateral thigh subcutaneous tissue. There is no requirement for pH adjustment; the peptide is stable in aqueous solution within the physiological pH range.

Frequently Asked Questions

Does Semax raise cortisol? No. Despite sharing sequence homology with ACTH, Semax lacks the N-terminal residues required to activate adrenal ACTH receptors (MC-two). It produces no measurable cortisol elevation at research-relevant doses.

Can Semax be combined with Selank? Yes, and this is one of the most commonly explored combinations in Russian nootropic research. The two peptides have complementary but non-overlapping mechanisms — Semax is predominantly activating and neurotrophic; Selank is predominantly anxiolytic and immunomodulatory. There is no known pharmacokinetic interaction.

How quickly does Semax work? Intranasal administration produces detectable CNS effects within fifteen to thirty minutes in most subjects, consistent with the olfactory-to-brain transport mechanism documented by Potaman and colleagues for ACTH-fragment analogues. Cognitive effects are typically reported as subtle on single doses and more pronounced with repeated use over five to ten days as BDNF and NGF upregulation accumulates.

Is there a risk of addiction? Current evidence does not support addiction potential. Semax does not directly release dopamine into the nucleus accumbens in the manner of classical addictive compounds, and no craving, withdrawal, or compulsive use pattern has been identified in decades of clinical use.

---

Explore Related Stacks

• Semax + Selank + Pinealon Nootropic Stack
• Cerebrolysin + Semax Cognitive Stack

Source research-grade Semax

Semax — ACTH(4-10) Heptapeptide Nootropic is sold for laboratory and in vitro research use only. UK regulatory status: Approved as a medicinal product in the Russian Federation (essential drugs list, post-stroke + cognitive rehabilitation indications). Unapproved in UK, US, EU — research use only..

Source on PeptideBarn.co.ukFull monograph on PeptideAuthority.co.uk